M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2

Recruiting

Conditions: Myelodysplastic Syndrome
Acute Myeloid Leukemia With Gene Mutations
Recurrent Acute Myeloid Leukemia
Myeloproliferative Neoplasm
Refractory Acute Myeloid Leukemia

Interventions: Drug: Ivosidenib
Drug: Liposome-encapsulated Daunorubicin-Cytarabine

First Posted Date: 2020-07-30

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT04493164

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Perioperative Care in the Cancer Patient -1, ARCA-1 Study

Completed

Conditions: Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Other: Best Practice
Other: Medical Chart Review

First Posted Date: 2020-07-29

Last Posted Date: 2023-11-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 229

Registration Number: NCT04491409

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce

Recruiting

Conditions: COVID-19 Infection

Interventions: Other: Questionnaire Administration

First Posted Date: 2020-07-29

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20000

Registration Number: NCT04491292

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Recurrent Acute Myeloid Leukemia
Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Refractory Chronic Myelomonocytic Leukemia
Refractory Myelodysplastic Syndrome

Interventions: Drug: Azacitidine
Drug: Trametinib
Drug: Venetoclax

First Posted Date: 2020-07-27

Last Posted Date: 2023-03-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT04487106

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Phase 1

Recruiting

Conditions: Resectable Pancreatic Ductal Adenocarcinoma
Borderline Resectable Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Ductal Adenocarcinoma
Stage III Pancreatic Cancer AJCC v8

Interventions: Other: Hafnium Oxide-containing Nanoparticles NBTXR3
Radiation: Radiation Therapy

First Posted Date: 2020-07-24

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT04484909

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Assessment of What Patients and Healthcare Providers Value

Completed

Conditions: Gastric Adenocarcinoma
Pancreatic Neuroendocrine Carcinoma
Pancreatic Adenocarcinoma

Interventions: Other: Survey Administration

First Posted Date: 2020-07-23

Last Posted Date: 2022-08-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 397

Registration Number: NCT04483349

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Phase 2

Active, not recruiting

Conditions: Borderline Resectable Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Ductal Adenocarcinoma
Resectable Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Fluorouracil
Drug: Cisplatin
Drug: Irinotecan
Drug: Leucovorin
Drug: Gemcitabine
Drug: Oxaliplatin
Radiation: Radiation Therapy
Drug: Nab-paclitaxel

First Posted Date: 2020-07-22

Last Posted Date: 2024-10-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 105

Registration Number: NCT04481204

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic

Phase 1

Active, not recruiting

Conditions: COVID-19 Infection

Interventions: Other: Media Intervention
Procedure: Meditation Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Yoga

First Posted Date: 2020-07-22

Last Posted Date: 2024-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT04482647

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors

Not Applicable

Recruiting

Conditions: Glioblastoma
WHO Grade II Glioma
WHO Grade III Glioma

Interventions: Other: Educational Intervention
Other: Questionnaire Administration
Other: Survey Administration
Other: Video

First Posted Date: 2020-07-21

Last Posted Date: 2024-12-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 102

Registration Number: NCT04479696

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Stage IIIB Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8
Recurrent Lung Non-Small Cell Carcinoma
Stage IVA Lung Cancer AJCC v8

Interventions: Drug: Alisertib
Drug: Osimertinib
Drug: Sapanisertib

First Posted Date: 2020-07-21

Last Posted Date: 2024-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT04479306

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy